人 SLC15A1 抗体对
01AB02103
Solute carrier family 15 member 1 (SLC15A1), also known as PepT1, is a proton-coupled oligopeptide transporter primarily localized to the brush border membrane of small-intestinal enterocytes. It mediates the electrogenic uptake of dietary di- and tripeptides from the intestinal lumen into the cytoplasm, utilizing an inward proton gradient to drive transport. Beyond its role in nitrogen assimilation, SLC15A1 is a major determinant of the pharmacokinetics of various peptidomimetic drugs, including β-lactam antibiotics and certain ACE inhibitors. It is also expressed in the kidney and gallbladder, where it contributes to peptide reabsorption. Clinically, dysregulation of SLC15A1 is implicated in intestinal inflammatory and metabolic conditions, as its activity influences both nutrient absorption and the delivery of therapeutic agents. Its function is essential for maintaining systemic protein balance and optimizing the oral bioavailability of peptide-like medications.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- SLC15A1
- 基因别名
- PEPT1
- 蛋白别名
- solute carrier family 15 member 1; SLC15A1
- UniProt
- P46059
- 物种
- Human
产品详情
- 靶点名称
- SLC15A1
- 蛋白名称
- solute carrier family 15 member 1
- 蛋白别名
- Solute carrier family 15 member 1; Intestinal H(+)/peptide cotransporter; Oligopeptide transporter; small intestine isoform; Peptide transporter 1
- 靶点基因名
- SLC15A1
- 基因别名
- PEPT1
- UniProt
- P46059
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Solute carrier family 15 member 1 (SLC15A1), also known as PepT1, is a proton-coupled oligopeptide transporter primarily localized to the brush border membrane of small-intestinal enterocytes. It mediates the electrogenic uptake of dietary di- and tripeptides from the intestinal lumen into the cytoplasm, utilizing an inward proton gradient to drive transport. Beyond its role in nitrogen assimilation, SLC15A1 is a major determinant of the pharmacokinetics of various peptidomimetic drugs, including β-lactam antibiotics and certain ACE inhibitors. It is also expressed in the kidney and gallbladder, where it contributes to peptide reabsorption. Clinically, dysregulation of SLC15A1 is implicated in intestinal inflammatory and metabolic conditions, as its activity influences both nutrient absorption and the delivery of therapeutic agents. Its function is essential for maintaining systemic protein balance and optimizing the oral bioavailability of peptide-like medications.